HB0025

HB0025 Plus Chemotherapy Shows Promise in Treating Advanced Non-Small Cell Lung Cancer: Insights From a Phase 2 Trial

HB0025, a bispecific antibody targeting PD-L1 and VEGF pathways, combined with chemotherapy, demonstrated encouraging efficacy and manageable safety in advanced non-small cell lung cancer patients, supporting further phase 3 evaluation.